A self-directed learning material to complete in your own time. With the PEMAZYRE learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.
▼ This medicinal product is subject to additional monitoring which will enable quick identification of new safety information. Healthcare professionals are required to report any suspected new or serious side effects. See the “Undesirable effects” section of the Swiss Professional Information for the terms and conditions for reporting side effects.
Intended for licensed healthcare professionals located in Switzerland.
You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third–party sites. Would you like to continue?